NCT00675350已完成1 期
A Pharmacokinetic Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
ChemGenex Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Pharmacokinetic Evaluation
研究概览
简要总结
PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
详细描述
This is an open-label non-randomized pharmacokinetic (PK) study of Homoharringtonine (Omacetaxine Mepesuccinate) administered as a subcutaneous (SC)injection to patients with relapsed and/or refractory hematologic malignancies and to patients with advanced solid tumors with no bone marrow involvement.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be ≥18 years old.
- •Be diagnosed with relapsed or refractory leukemia including chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS)
- •Relapsed defined as reappearance of leukemic blasts in the peripheral blood or the finding of ≥5% blasts in the bone marrow, not attributable to another cause (e.g., bone marrow regeneration after consolidation therapy).
- •Refractory defined as no response to previous combined chemotherapy regimens including at least one cytarabine plus one anthracycline advanced solid tumors (i.e., breast, lung, head / neck, colorectal, melanoma, and sarcoma). Patients must have exhausted or become intolerant to all available therapies.
- •(Patients with hematologic malignancies): Have completed all previous anti-leukemic therapy (except leukapheresis) at least 2 weeks prior to the first planned dose of OMA and must have fully recovered from side effects of a previous therapy unless, disease progression necessitates early therapy. Leukapheresis is allowed up to 24 hours prior to registration.
- •(Patients with solid tumors): Patients may have measurable or unmeasurable disease. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥20 mm with conventional computerized tomography (CT) or magnetic resonance imaging (MRI) scans, or as ≥10 mm with spiral computerized tomography (CT) scan. Imaging must be performed within 28 days of the first dose of study drug.
- •Have an estimated life expectancy of ≥12 weeks
- •Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤2 (see Appendix B)
- •Be able to provide written informed consent prior to enrollment into the study. In the event that the patient is re-screened for study participation or a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed.
- •Be male or a non-pregnant, non-lactating female. Fertile patients must agree to use an effective barrier method contraception (e.g., latex condom, diaphragm, or cervical cap) to avoid pregnancy while on therapy and for 6 months following the discontinuation of the study drug.
- •A non-fertile female is defined as:
- •Postmenopausal (amenorrheic for ≥12 months) Undergone a complete oophorectomy or hysterectomy.
- •Have a negative serum pregnancy test within 7 days prior to the first dose of study drug (if patient is a female of childbearing potential).
- •QTc <450 ms on screening 12-lead ECG (using Bazett's correction of QT interval formula [QTcB]).
- •Have adequate organ function as indicated by the following laboratory values obtained within 7 days prior to the first dose of study drug as outlined in Table
- •Be able and willing to comply with the requirements of the entire study.
排除标准
- •Received previous treatment with OMA within 6 months of study entry.
- •Have New York Heart Association (NYHA) Class 3 or 4 heart disease, active ischemia, or any uncontrolled, unstable cardiac condition for which treatment for the condition is indicated but is not controlled despite adequate therapy, including angina pectoris, cardiac arrhythmia, hypertension, or congestive heart failure (see Appendix D).
- •Experienced a myocardial infarction in the previous 12 weeks.
- •Have solid tumors with known bone marrow or central nervous system (CNS) involvement.
- •Have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.
- •Are pregnant or lactating.
- •Received systemic chemotherapy in the 4 weeks prior to first dose of study drug, unless treatment is required for progressive leukemia. In patients with rapidly proliferating disease, hydroxyurea may be administered immediately prior to and during the first two cycles of treatment, if clinically indicated, to control disease.
- •Received radiation therapy within 6 weeks of the first dose of study drug. Localized radiation for palliation may be administered with 2 weeks of the first dose of study drug.
- •Have any medical condition or psychiatric disorder(s) rendering the patient unable to understand the nature, scope, and possible consequences of the study.
研究组 & 干预措施
Homoharringtonine
Experimental
干预措施: Omacetaxine (Drug)
结局指标
主要结局
Pharmacokinetic Evaluation
时间窗: 28 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy SubjectsHealthyNCT01451229Peking Union Medical College Hospital10
进行中（未招募）
1 期
Pharmacokinetic study on echinocandins for patients with septic shock following secondary peritonitisEUCTR2016-002708-17-FRCHU de NIMES24
已完成
1 期
Single and Multiple Doses of an Oral Formulation of L-Homoarginine in Healthy Human SubjectsHealthyNCT02675660Universitätsklinikum Hamburg-Eppendorf20
已完成
1 期
Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 CapsuleHealthyNCT01548157Hanmi Pharmaceutical Company Limited28
已完成
1 期
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy ParticipantsHealthy VolunteersNCT06746402Bristol-Myers Squibb42